PubMed
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
Compare
FOXO4-DRI vs MK-677
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
FOXO4-DRI
28 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
178
Energy
178
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
58
2+ mg
120
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 194 days · Based on 26 repeat reporters
MK-677
24 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
135
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
2
Fatigue
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
135
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 91% said they felt similar to their last entry, 9% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 156 days · Based on 22 repeat reporters
Sources (8)
Published sources linked on the FOXO4-DRI and MK-677 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born E, Lipskaia L, Breau M, et al. Circulation. 2023
- Wiki study page →Source
PubMed
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
- Wiki study page →Source
PubMed
MK-677, an orally active growth hormone secretagogue: effects on body composition
Murphy MG, Plunkett LM, Gertz BJ, et al. J Clin Endocrinol Metab. 1998
- Wiki study page →Source
PubMed
Two-year treatment with ibutamoren increases bone mineral density, body composition, and quality of life
Nass R, Pezzoli SS, Oliveri MC, et al. J Clin Endocrinol Metab. 2008
- Wiki study page →Source
ClinicalTrials.gov
Ibutamoren (MK-677) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
Murphy MG, Plunkett LM, Gertz BJ, et al. The Journal of clinical endocrinology and metabolism. 1998
- Wiki study page →Source
PubMed
Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control
Philip M, Karakka Kal AK, Subhahar MB, et al. Rapid communications in mass spectrometry : RCM. 2022